Piribedil: Antiparkinsonian Properties and Potential Clinical Utility in Dopaminergic Disorders
Keywords: Adrenergic antagonist; CNS disease; N-oxidation; Parkinson's disease; absorption; acetylcholinesterase inhibitors (AChEi); alopecia; anxiety; attention; axial symptoms; basal ganglia; bioavailability; bitter taste; brains; catechol; cognitive dysfunction; colon; crystalline; dementia; depression; dopamine agonist; dopamine receptors; dorsal raphe nucleus (DRN); dose; dose-dependent receptor; drug exposures; drug repositioning; dysfunction; dyskinesias; dystonia; elimination; executive functions; frontotemporal dementia; half-life; hypotension; insomnia; isoenzymes; levodopa; locus coeruleus; nausea; neurodegenerative disorder; neurons; odorless; oral; peripheral edema; pharmacokinetics; plasma; plasma levels; properties; psychosis; renal excretion; schizophrenia; smoking cessation; somnolence; striatal dopamine; sublingual; suboptimal dosing; substantia nigra pars compacta; tremor; urine
Document Type: Research Article
Publication date: 01 February 2011
- Current Drug Therapy publishes frontier reviews on all the latest advances in drug therapy. The journal's aim is to publish the highest quality review articles in the field. Topics covered include: new and existing drugs, therapies and medical devices.
The journal is essential reading for all researchers and clinicians involved in drug therapy.
- Editorial Board
- Information for Authors
- Subscribe to this Title
- Ingenta Connect is not responsible for the content or availability of external websites